Literature DB >> 7248119

Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation.

J Evenhuis, S Agoston, P J Salt, A R de Lange, W Wouthuyzen, W Erdmann.   

Abstract

The concentrations of 4-aminopyridine hydrochloride in the blood and urine from volunteers were measured following a bolus injection i.v. of 0.3 mg kg-1. The drug was assayed by means of a new GLC method which is described. The pharmacokinetics of 4-aminopyridine are complicated by an additional increase in plasma concentration during the elimination phase of the drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248119     DOI: 10.1093/bja/53.6.567

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.

Authors:  Carrie Hersh; Alex Rae-Grant
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

2.  Antagonism of d-tubocurarine-induced neuromuscular blockade with a mixture of 4-aminopyridine and neostigmine in man.

Authors:  K Wirtavuori; M Salmenperä; T Tammisto
Journal:  Can Anaesth Soc J       Date:  1984-11

3.  Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat.

Authors:  Anthony Caggiano; Andrew Blight; Tom J Parry
Journal:  J Drug Assess       Date:  2013-04-12

4.  In vitro evaluation of the effects of 4-aminopyridine on cytochrome P450 enzymes.

Authors:  Anthony Caggiano; Andrew Blight
Journal:  J Drug Assess       Date:  2013-03-26

5.  Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways.

Authors:  Anthony Caggiano; Andrew Blight
Journal:  J Drug Assess       Date:  2013-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.